Ago2 Antibody, Brachyury Antibody, Brn3A Antibody, Cd45Ro Antibody, Cdk5 Antibody, Erg Antibody, Foxa2 Antibody, Galr1 Antibody, Gerbil, Goat, Guinea, Hamster, Helicobacter, Human, Influenza, Insect, Kangaroo, Klf2 Antibody, Lkb1 Antibody, Mobp Antibody, Pig, Rabbit, Raccoon, Rat, Reindeer, Tbp Antibody, Zeb2 Antibody

Two microassays for determination of a wide range of proteolytic activities using Azocoll as substrate

Two micromethods for measuring proteolytic activity were developed. A semiquantitative assay on microtitre plates with granular Azocoll as substrate is based on the determination of the time of first appearance of pink colour, t, in the reaction mixture and proteolytic activity is expressed as 1/t. This simple, sensitive and economical method is convenient for preliminary testing of a large number of small samples with unknown proteolytic activity, such as fractions after chromatography.
It speeds up considerably proteinase purification. The other test, a quantitative microassay, is a low-cost and time-saving version of the classical method which reduces material consumption and includes automated measurement of absorbance in microtitre plates by a Multiscan reader. Application of these methods are demonstrated.

Diagnostic and prognostic impact of Cytokeratin 19 expression analysis in human tumors: A tissue microarray study of 13,172 tumors

To evaluate cytokeratin 19 expression in normal and cancerous tissues, 15,977 samples from 122 tumor types and 608 samples of 76 normal tissue types were analyzed by immunohistochemistry. In normal tissues, CK19 expression occurred in epithelial cells of most glandular organs but was strictly limited to the basal cell layer of non-keratinizing squamous epithelium and absent in the skin. CK19 expression in ≥90% of cases was seen in 34% of the tumor entities including the adenocarcinomas of the pancreas (99.4%), colorectum (99.8%), esophagus (98.7%), and stomach (97.7%) as well as breast cancer (90.0%-100%), high grade serous (99.1%) or endometroid (97.8%) ovarian cancer, and urothelial carcinoma (92.6%-100%). A low CK19 positivity rate (0.1-10%) was seen in 5 of 122 tumor entities including hepatocellular carcinoma and seminoma.

A comparison of tumor versus normal tissue findings demonstrated that up-regulation and down-regulation of CK19 can occur in cancer and that both alterations can be linked to unfavorable phenotype. CK19 down regulation was linked to high grade (p=0.0017) and loss of ER- and PR-expression (p<0.0001 each) in invasive breast carcinoma of no special type. CK19 up regulation was linked to nodal metastases in neuroendocrine tumors and papillary thyroid carcinomas (p<0.05 each) and to poor grade in clear cell renal cell carcinoma (p<0.05). CK19 up regulation was particularly common in squamous cell carcinomas. We concluded that CK19 immunohistochemistry might separate primary liver cell carcinoma from liver metastases, seminoma from other testicular tumors, and helps in the detection of early neoplastic transformation in squamous epithelium.

 

Tissue microarray profiling and integrative proteomics indicate the modulatory potential of Maytenus royleanus in inhibition of overexpressed TPD52 in prostate cancers

 

  • Maytenus roylanus (MEM) is a plant with anti-proliferative effects against prostate cancer. We aimed to explore the mechanism of action of MEM in prostate cancer (PCa) by employing an in vitro global proteome approach to get useful information of various signaling pathways and effected genes to define the mechanism of MEM action in prostate cancer.
  • We conducted a global proteome analysis of CWR22Rv1after treatment with methanolic extract of MEM. The result of the proteomic profiling of in vitro PCa cells demonstrated the reduction in tumor protein D52 (TPD52) expression after treatment with methanolic extract of MEM.
  • Down-regulation of TPD52 expression at mRNA level was observed by MEM treatment in CWR22Rν1 and C4-2cells in a dose-dependent fashion probably by cleavage of Caspase 3 and PARP, or by modulation of cyclin-dependent kinases in CWR22Rν1 and C4-2 
  • The progressive character of the TRAMP model demonstrates a chance to evaluate the potential of chemo-preventive agents for both initial and late stages of prostate cancer development, and induction in TPD52 protein expression with development as well as the progression of prostate cancer was observed in the TRAMP model.
  • Analyses of the tissue microarray collection of 25 specimens confirmed the clinical significance of our findings identifying TPD52 as a potential marker for PCa progression.
  • We determined that knockdown of TPD52 (CWR22Rν1 cells), a considerable downregulation was seen at the protein level.
  • Downregulation of TPD52 inhibited the migration and invasive behavior of prostate cancer cells as observed. Moreover, we observed that the siRNA-TPD52 transfection of CWR22Rν1 cells resulted in tumor growth inhibition with a marked reduction in the secretion of prostatespecific antigen (PSA) in the serum.
  • Intraperitoneal injection of MEM considerably slowed tumor growth in athymic mice, inhibited TPD52 expression, and caused a marked reduction in PSA levels of serum as demonstrated by immunoblot screening and immune-histochemical staining. This report illustrates a molecular overview of pathological processes in PCa, indicating possible new disease biomarkers and therapeutic targets.

Comprehensive analysis of glycosphingolipid glycans by lectin microarrays and MALDI-TOF mass spectrometry

 

Glycosphingolipids (GSLs) are ubiquitous glycoconjugates present on the cell membrane; they play significant roles in many bioprocesses such as cell adhesion, embryonic development, signal transduction and carcinogenesis. Analyzing such amphiphilic molecules is a major challenge in the field of glycosphingolipidomics. We provide a step-by-step protocol that uses a lectin microarray to analyze GSL glycans from cultured cells.

The procedure describes (i) extraction of GSLs from cell pellets, (ii) N-monodeacylation using sphingolipid ceramide N-deacylase digestion to form lyso-GSLs, (iii) fluorescence labeling at the newly exposed amine group, (iv) preparation of a lectin microarray, (v) GSL-glycan analysis by a lectin microarray, (vi) complementary mass spectrometry analysis and (vii) data acquisition and analysis. This method is high-throughput, low cost and easy to conduct, and it provides detailed information about glycan linkages. This protocol takes ~10 d.

Value of chromosomal microarray analysis for the prenatal diagnosis of pregnancy with high risk signaled by non-invasive prenatal testing

 

Objective: To explore the value of chromosomal microarray analysis (CMA) for the diagnosis of fetuses with high risk signaled by non-invasive prenatal testing (NIPT).

Methods: From June 2017 to August 2019, 628 pregnant women with high risk signaled by NIPT underwent invasive prenatal diagnosis. Amniotic fluid or cord blood samples were subjected to chromosomal karyotyping analysis or CMA. Pregnancy outcome and postnatal conditions of the fetuses were followed up.

Results: The positive predictive value for trisomy 21, trisomy 18, trisomy 13, sex chromosome aneuploidy, other rare trisomies and copy number variants (CNVs) among the 628 women were 86.4% (127/147), 41.7% (30/72), 12.9% (4/31), 43.7% (101/231), 16.5% (14/85) and 52.2% (35/67), respectively. In 218 samples with normal karyotype, 5.5% (12/218) of additional pathogenic CNVs and 2.3% (5/218) of loss of heterozygosity were detected by CMA.

 

expressionpathology
expressionpathology

E-Cadherin expression in human tumors: a  tissue microarray study on 10,851 tumors

Background: The E-Cadherin gene (CDH1, Cadherin 1), located at 16q22.1 encodes for a calcium-dependent membranous glycoprotein with an important role in cellular adhesion and polarity maintenance.

Methods: To systematically determine E-Cadherin protein expression in normal and cancerous tissues, 14,637 tumor samples from 112 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format.

Results: E-Cadherin was strongly expressed in normal epithelial cells of most organs. From 77 tumor entities derived from cell types normally positive for E-Cadherin, 35 (45.5%) retained at least a weak E-Cadherin immunostaining in ≥99% of cases and 61 (79.2%) in ≥90% of cases. Tumors with the highest rates of E-Cadherin loss included Merkel cell carcinoma, anaplastic thyroid carcinoma, lobular carcinoma of the breast, and sarcomatoid and small cell neuroendocrine carcinomas of the urinary bladder.

Reduced E-Cadherin expression was linked to higher grade (p = 0.0009), triple negative receptor status (p = 0.0336), and poor prognosis (p = 0.0466) in invasive breast carcinoma of no special type, triple negative receptor status in lobular carcinoma of the breast (p = 0.0454), advanced pT stage (p = 0.0047) and lymph node metastasis in colorectal cancer (p < 0.0001), and was more common in recurrent than in primary prostate cancer (p < 0.0001). Of 29 tumor entities derived from E-Cadherin negative normal tissues, a weak to strong E-Cadherin staining could be detected in at least 10% of cases in 15 different tumor entities (51.7%).

 

Tumors with the highest frequency of E-Cadherin upregulation included various subtypes of testicular germ cell tumors and renal cell carcinomas (RCC). E-Cadherin upregulation was more commonly seen in malignant than in benign soft tissue tumors (p = 0.0104) and was associated with advanced tumor stage (p = 0.0276) and higher grade (p = 0.0035) in clear cell RCC, and linked to advanced tumor stage (p = 0.0424) and poor prognosis in papillary RCC (p ≤ 0.05).

Conclusion: E-Cadherin is consistently expressed in various epithelial cancers. Down-regulation or loss of E-Cadherin expression in cancers arising from E-Cadherin positive tissues as well as E-Cadherin neo-expression in cancers arising from E-Cadherin negative tissues is linked to cancer progression and may reflect tumor dedifferentiation.

 

Mouse Neuronal Tissue Paraffin Microarray

MAP-200 5 slides
EUR 461

Mouse Digestive Tissue Paraffin Microarray

MAP-300 5 slides
EUR 377

Mouse Mixed Tissue Paraffin Microarray, Panel #1

MAP-MT1 5 slides
EUR 411

Mouse Mixed Tissue Paraffin Microarray, Panel #2

MAP-MT2 5 slides
EUR 411

Mouse Mixed Tissue Paraffin Microarray, Panel #3

MAP-MT3 5 slides
EUR 596

Rat Neuronal Tissue Paraffin Microarray

RAP-200 5 slides
EUR 461

Rat Digestive Tissue Paraffin Microarray

RAP-300 5 slides
EUR 377

Rat Mixed Tissue Paraffin Microarray, Panel #1

RAP-MT1 5 slides
EUR 411

Rat Mixed Tissue Paraffin Microarray, Panel #2

RAP-MT2 5 slides
EUR 411

Rat Mixed Tissue Paraffin Microarray, Panel #3

RAP-MT3 5 slides
EUR 596

Tissue, Array, Human Adult Normal, Multi, tissue (8) VIII, Reproductive, testis, epididymis, ductus deferens, Seminal vesicle, ovary, fallopian tube, uterus, vagina (Paraffin)

MBS639617-5Arrays 5Arrays
EUR 495

Tissue, Array, Human Adult Normal, Multi, tissue (8) VIII, Reproductive, testis, epididymis, ductus deferens, Seminal vesicle, ovary, fallopian tube, uterus, vagina (Paraffin)

MBS639617-5x5Arrays 5x5Arrays
EUR 2075

Panel 5: Mouse CD1 Reproductive Tissue Premade Western Blot

MW-MT-5 1 Blot
EUR 601

Panel 5: Mouse C57 Reproductive Tissue Premade Western Blot

MW-MT-5-C57 1 Blot
EUR 722

Panel 5: Mouse CD1 Reproductive Tissue Premade Northern Blot

MN-MT-5 1 Blot
EUR 601

Panel 5: Mouse C57 Reproductive Tissue Premade Northern Blot

MN-MT-5-C57 1 Blot
EUR 789

Reproductive Tissue Dissociation System 10 (Pituitary), Adult mouse

4-20420 ea Ask for price

Reproductive Tissue Dissociation System 3 (Uterine), Mouse and Rat

4-20413 ea Ask for price

Reproductive Tissue Dissociation System 17 (Sertoli), Mouse and Rat

4-20426 ea Ask for price

Reproductive Tissue Dissociation System 18 (Uterine), Mouse and Rat

4-20427 ea Ask for price

Reproductive Tissue Dissociation System 7 (Prostate), Mouse and Rat

4-20417 ea Ask for price

Mouse FibrOut 7, for reproductive tissues

4-20513 1 ml Ask for price

Mouse FibrOut 7, for reproductive tissues

4-20514 5 x 1 ml Ask for price

Reproductive Tissue Dissociation System 9 (Epithelial), Mouse and Rat

4-20419 ea Ask for price

Reproductive Tissue Dissociation System 15 (Myometrial), Mouse and Rat

4-20424 ea Ask for price

Mouse Neuronal Tissue Frozen Microarray

MAF-200 5 slides
EUR 461

Mouse Digestive Tissue Frozen Microarray

MAF-300 5 slides
EUR 377

Female reproductive system tissue array

FRS801 each
EUR 306
Description: Female reproductive system tissue array, with stage and grade info, 80 cases/80 cores

Reproductive Tissue Dissociation System 11 (Leydig,Testis), Mouse and Rat

4-20421 ea Ask for price

Reproductive Tissue Dissociation System 12 (Corpus Leuteum), Mouse and Rat

4-20422 ea Ask for price

Reproductive Tissue Dissociation System 19 (Luteal, ovaries), Mouse and Rat

4-20428 ea Ask for price

Reproductive Tissue Dissociation System 4 (Epithelial, vagina), Mouse and Rat

4-20414 ea Ask for price

Reproductive Tissue Dissociation System 2 (Seminiferous tubules), Mouse and Rat

4-20412 ea Ask for price

Reproductive Tissue Dissociation System 8 (Epithelial,Mesencymal), Mouse and Rat

4-20418 ea Ask for price

Female reproductive system tumor tissue array

FE951 each
EUR 354
Description: Female reproductive system tumor tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), 95 cases/95 cores (core size 1.5mm), Recent Year Collection

Panel 5: Rat Reproductive Tissue Premade Western Blot

RW-MT-5 1 Blot
EUR 601

Mouse Mixed Tissue Frozen Microarray, Panel #1

MAF-MT1 5 slides
EUR 411

Mouse Mixed Tissue Frozen Microarray, Panel #2

MAF-MT2 5 slides
EUR 411

Mouse Mixed Tissue Frozen Microarray, Panel #3,

MAF-MT3 5 slides
EUR 596

Panel 5: Rat Reproductive Tissue Premade Northern Blot

RN-MT-5 1 Blot
EUR 601

Reproductive Tissue Dissociation System 6 (Epithelial, prostate gland), Mouse and Rat

4-20416 ea Ask for price

Reproductive Tissue Dissociation System 5 (Cumulus, one-cell embryos), Mouse and Rat

4-20415 ea Ask for price

Universal control tissue microarray

CTRL141 each
EUR 54
Description: Universal control tissue microarray, 7 types of Immune System normal tissues, 7 cases/14 cores

Rat FibrOut 7, for reproductive tissues

4-20537 1 ml Ask for price

Rat FibrOut 7, for reproductive tissues

4-20538 5 x 1 ml Ask for price

Stomach adenocarcinoma tissue microarray

ST991b each
EUR 270
Description: Stomach adenocarcinoma tissue microarray, including TNM, clinical stage and pathology grade, 33 cases/ 99cores, replacing ST991a

Human FibrOut 7, for reproductive tissues

4-21558 1 ml Ask for price

Human FibrOut 7, for reproductive tissues

4-21559 5 x 1 ml Ask for price

Rat Neuronal Tissue Frozen Microarray

RAF-200 5 slides
EUR 461

Rat Digestive Tissue Frozen Microarray

RAF-300 5 slides
EUR 377

Reproductive Tissue Dissociation System 16 (Mesothelial and surface epithelial Ovaries), Mouse and Rat

4-20425 ea Ask for price

Reproductive Tissue Dissociation System 13 (Interna & corpus lutem,endometrium Ovarian, uterine), Mouse and Rat

4-20423 ea Ask for price

Rat Mixed Tissue Frozen Microarray, Panel #1

RAF-MT1 5 slides
EUR 411

Rat Mixed Tissue Frozen Microarray, Panel #2

RAF-MT2 5 slides
EUR 411

Rat Mixed Tissue Frozen Microarray, Panel #3,

RAF-MT3 5 slides
EUR 596

Reproductive Tissue Dissociation System 14 (Ovarian surface epithelial and peritoneal mesothelial), Mouse and Rat

4-20429 ea Ask for price

High density tissue microarray of Hodgkin's Disease

LM208 each
EUR 546
Description: High density tissue microarray of Hodgkin's Disease, Non-Hodgkin's lymphoma and normal lymph node tissues, 69 cases/208 cores

Reproductive Tissue Dissociation System 1 (Epithelial,Leydig, Luteal, ovaries, Sertolli, seminiforous tubules), Mouse and Rat

4-20411 ea Ask for price

Tissue microarray of top 4 types of cancer (colon

TP484 each
EUR 198
Description: Tissue microarray of top 4 types of cancer (colon, breast, prostate and lung) and normal tissue, 24 cases/48 cores

Stomach carcinoma with matched stomach tissue microarray

ST2084b each
EUR 546
Description: Stomach carcinoma with matched stomach tissue microarray, containing 94 cases of adenocarcinoma, 1 each of signet ring cell carcinoma and squamous cell carcinoma, duplicated cores per case

Normal human tissue microarray from 12 organs from autopsy

BN482 each
EUR 234
Description: Normal human tissue microarray from 12 organs from autopsy, 24 cases/48 cores

EZ-TMA Manual Tissue Microarray Kit 3 - 3 mm x 24 Core

IW-123 -
EUR 125

EZ-TMA Manual Tissue Microarray Kit 4 - 4 mm x 15 Core

IW-124 -
EUR 125

Skin cancer and normal tissue high density (69 cases/208 core) tissue microarray

SK208 each
EUR 546
Description: Skin cancer and normal tissue high density (69 cases/208 core) tissue microarray

Colon cancer tissue microarray chip with survival data, 80 cases/80 cores.

S-CRAC1601C row: 8; column: 10; cores: 80; cases: 80
EUR 816

Brain primary tumor high density (69 cases/208 cores) tissue microarray of astrocytoma

GL208 each
EUR 546
Description: Brain primary tumor high density (69 cases/208 cores) tissue microarray of astrocytoma, glioblastoma, glioblastoma multiforme (GBM) and normal tissue

Rhox-2 (Reproductive Homeobox on X Chromosome 2, Reproductive Homeobox (Rhox) 2)

MBS6003132-01mL 0.1(mL
EUR 570

Rhox-2 (Reproductive Homeobox on X Chromosome 2, Reproductive Homeobox (Rhox) 2)

MBS6003132-5x01mL 5x0.1mL
EUR 2410
Frank Green